Listeria-based immunotherapy directed against CD105 exerts anti-angiogenic and anti-tumor efficacy in renal cell carcinoma

Targeting tumor-associated angiogenesis is currently at the forefront of renal cell carcinoma (RCC) therapy, with sunitinib and bevacizumab leading to increased survival in patients with metastatic RCC (mRCC). However, resistance often occurs shortly after initiation of therapy, suggesting that targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Oladejo, Mariam, Nguyen, Hong-My, Silwal, Ashok, Reese, Britney, Paulishak, Wyatt, Markiewski, Maciej M., Wood, Laurence M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692019/
https://www.ncbi.nlm.nih.gov/pubmed/36439126
http://dx.doi.org/10.3389/fimmu.2022.1038807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692019/
https://www.ncbi.nlm.nih.gov/pubmed/36439126
http://dx.doi.org/10.3389/fimmu.2022.1038807

Ejemplares similares